LDLR and chronic kidney disease: A meta-analysis of the MR results from the three databases revealed a significant association between LDLR agonists and an increased risk of CKD (OR [95% CI] = 1.11 [1.02 - 1.22]), as well as a significant association between ANGPTL3 inhibitors and a reduced risk of CKD (OR [95% CI] = 0.85 [0.75-0.96]).